SuperGen ceo joins BIO board
James Manuso joins the US-based biotechnology organisation
BIO’s board includes members of the governing boards for each of the organisation’s four sections: health, emerging companies, industrial and environmental and food and agriculture. Manuso has joined BIO’s health section governing board.
In addition, Manuso will serve on the BIO board Standing Committee on International Affairs.
SuperGen has been a member of BIO since 2003.
Manuso has been SuperGen chairman, president and chief executive since January 2004. He is co-founder and immediate past president and chief executive of Galenica Pharmaceuticals.
The Biotechnology Industry Organization (BIO) represents more than 1,100 biotechnology companies, academic institutions, biotechnology centres and related organisations across the US and in more than 30 other nations.
BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
You may also like
Regulatory
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions
Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Pharmaceutical
Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026
Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
Regulatory
FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths
The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
Regulatory
NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer
MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this perioperative setting and the first treatment advance in more than two decades